Table 1 Characteristics of patients in the training and validation series
From: Predicting a local recurrence after breast-conserving therapy by gene expression profiling
Characteristic | Training | Validation | All |
|---|---|---|---|
No. of patients | 81 | 80 | 161 |
Non-local recurrence | 72 (89%) | 72 (90%) | 144 (89%) |
Local recurrence | 9 (11%) | 8 (10%) | 17 (11%) |
Tumor size T1/T2 | 50/31 (62%/38%) | 48/32 (60%/40%) | 98/63 (61%/39%) |
pN0/pN+ | 46/35 (57%/43%) | 44/36 (55%/45%) | 90/71 (56%/44%) |
Grade I/II/III | 22/26/33 (27%/32%/41%) | 21/28/31 (26%/35%/39%) | 43/54/64 (27%/33%/40%) |
Age <40 years | 62 (77%) | 64 (80%) | 126 |
Follow-up (years) | 7.87 | 7.56 | 7.69 |
Metastasis | 26 (32%) | 23 (29%) | 49 (30%) |
Chemotherapy | 28 (35%) | 30 (38%) | 58 (36%) |
Hormonal therapy | 10 (12%) | 8 (10%) | 18 (11%) |
ER+/ER- | 66/15 (81%/19%) | 55/25 (69%/31%) | 121/40 (75%/25%) |
Median RT dose (Gy) | 50 | 50 | 50 |
Median boost dose (Gy) | 15 | 15 | 15 |
Boost, yes/no | 70/11 (86%/16%) | 74/6 (93%/7%) | 144/17 (89%/11%) |
Margins infiltrating carcinomaa | 73, 4, 4 (90%, 5%, 5%) | 72, 3, 5 (90%, 4%, 6%) | 145, 7, 9 (90%, 4%, 6%) |
Margins DCISb | 25, 48, 3, 5 (31%, 59%, 4%, 6%) | 27, 41, 7, 5 (34%, 51%, 9%, 6%) | 52, 89, 10, 10 (33%, 55%, 6%, 6%) |